Details for Patent: 8,778,324
✉ Email this page to a colleague
Which drugs does patent 8,778,324 protect, and when does it expire?
Patent 8,778,324 protects VELTASSA and is included in one NDA.
This patent has ninety-six patent family members in seventeen countries.
Summary for Patent: 8,778,324
| Title: | Ion binding polymers and uses thereof |
| Abstract: | The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. |
| Inventor(s): | Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (Los Gatos, CA) |
| Assignee: | Relypsa, Inc. (Redwood City, CA) |
| Application Number: | 13/647,690 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,778,324 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 8,778,324
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-004 | Oct 2, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERKALEMIA | ⤷ Subscribe | ||||
| Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-001 | Oct 21, 2015 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERKALEMIA | ⤷ Subscribe | ||||
| Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-002 | Oct 21, 2015 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERKALEMIA | ⤷ Subscribe | ||||
| Vifor Pharma | VELTASSA | patiromer sorbitex calcium | POWDER;ORAL | 205739-003 | Oct 21, 2015 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERKALEMIA | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,778,324
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1732523 | ⤷ Subscribe | 300924 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2269589 | ⤷ Subscribe | CA 2018 00003 | Denmark | ⤷ Subscribe |
| European Patent Office | 1732523 | ⤷ Subscribe | 300925 | Netherlands | ⤷ Subscribe |
| European Patent Office | 1732523 | ⤷ Subscribe | 122018000011 | Germany | ⤷ Subscribe |
| European Patent Office | 1732523 | ⤷ Subscribe | 2018C/004 | Belgium | ⤷ Subscribe |
| European Patent Office | 1732523 | ⤷ Subscribe | C01732523/01 | Switzerland | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
